Prostate cancer is a serious disease in terms of its high incidence and mortality rate in the USA and around the world. The prostate specific antigen (PSA) has been used for prostate cancer diagnosis and follow-up of treatment but a number of challenges remain. Epigenetic biomarkers, especially methylation and microRNA (miR) biomarkers provide an opportunity for diagnosis, prognosis, and recurrence of prostate cancer. Differential global methylation has shown some promising results. In this chapter, the emphasis is given on those biomarkers which can be assayed noninvasively in a prospective study and in a clinic. Challenges in the field, especially the validation of potential biomarkers, and their potential solutions are provided in this chapter.
CITATION STYLE
Banerjee, H. N., Kahan, W., Kumar, V., & Verma, M. (2018). Methylation and microRNA profiling to understand racial disparities of prostate cancer. In Methods in Molecular Biology (Vol. 1856, pp. 255–267). Humana Press Inc. https://doi.org/10.1007/978-1-4939-8751-1_15
Mendeley helps you to discover research relevant for your work.